Sebaceous carcinoma: controversies and their evidence for clinical practice

Kibbi, Nour; Worley, Brandon; Owen, Joshua L.; Kelm, Ryan C.; Bichakjian, Christopher K.; Chandra, Sunandana; Demirci, Hakan; Kim, John; Nehal, Kishwer S.; Thomas, J. Regan; Poon, Emily; Alam, Murad

doi:10.1007/s00403-019-01971-4

Cited by 25 publications

(30 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current research is focused toward targeted therapies including regulation of the retinoic acid receptor beta, androgen receptor, and epidermal growth factor receptor. Combinations of androgen receptor antagonists, retinoic acid receptor agonists, and/or immunotherapy with anti-PD1 antibodies may prove beneficial as more prospective evidence emerges [27].…”

Section: Case Discussionmentioning

confidence: 99%

“…Muir-Torre Syndrome is characterized by the presence of at least one sebaceous gland neoplasm (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas) and at least one visceral malignancy [28]. Because the sebaceous neoplasm is often the first malignancy identified, screening for MTS becomes crucial to identify patients who require additional cancer surveillance and genetic testing [27]. Some experts urge for tumor testing of all sebaceous carcinomas for MMR defects and microsatellite instability to assess for risk of MTS, whereas others argue that the clinical utility of these tests remains unclear [29,30].…”

Section: Case Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extraocular sebaceous carcinoma as a rapidly growing back mass: a case report

Lipman¹,

Franck²,

Brownstone³

et al. 2020

Dermatology Online Journal

View full text Add to dashboard Cite

Section: Case Discussionmentioning

confidence: 99%

Section: Case Discussionmentioning

confidence: 99%

Extraocular sebaceous carcinoma as a rapidly growing back mass: a case report

Lipman¹,

Franck²,

Brownstone³

et al. 2020

Dermatology Online Journal

View full text Add to dashboard Cite

“…Some authors report that subclinical nodal spread is rare for EOSC and few SLNBs are positive (57)(58)(59), while others argue that EOSC is a locally aggressive tumor with a high likelihood of regional nodal metastasis and that regional nodal dissection together with a wide local excision should be considered optimal (55). For optimal treatment, SLNB may be helpful in determining subclinical lymphatic involvement in high-risk patients, particularly those with tumors thicker than two millimeters, tumors with a Clark stage over 4, lymphovascular invasion, perineural invasion, bone infiltration, and anaplasia or poorly differentiated tumors (55,60). Although the role of adjuvant radiotherapy is controversial, radiotherapy can be given after complete tumor resection either alone or in combination with chemotherapy (55).…”

Section: Discussionmentioning

confidence: 99%

“…Although the role of adjuvant radiotherapy is controversial, radiotherapy can be given after complete tumor resection either alone or in combination with chemotherapy (55). Primary radiotherapy alone is not recommended due to high recurrence rates (56,58,60). It can be used in patients who refuse surgery or cannot undergo surgery due to comorbidities, and there are also publications that recommend its postoperative use after resection (55).…”

Section: Discussionmentioning

confidence: 99%

A 20-Year Retrospective Analysis of Skin Cancers: Comparison of the First and Second Decades

Derebaşınlıoğlu

Karaca

2020

Konuralp Tıp Dergisi

View full text Add to dashboard Cite

The incidence of skin cancer increases day by day depending on environmental factors. Developing diagnostic and pathological methods provide correct typing of skin cancers. Methods: This retrospective analysis included patients who presented to and were scheduled for treatment at Sivas Cumhuriyet University Plastic Reconstructive and Aesthetic Surgery Clinic between January 1, 2000 and December 31, 2019 due to skin cancer and carcinoma in situ. The results were divided two groups as first ten years and second ten years. The groups were compared among themself in terms of cancer type, age, gender and localization. Results: 619 cases of 652 skin cancer and in situ carcinoma results were detected. When the groups were compared in terms of tumor types detected, there was a significant increase in MM, Bowen's disease, and rare NMSC subtypes other than SCC and BCC in the second decade (p<0.001). Comparison of NMSC and MSC rates between the groups showed that the incidence of MSC had increased significantly from 5.2% to 10% in the past 10 years (p<0,05). Conclusions: Rare Non-melanocytic skin cancer group includes many types of carcinoma, there are various treatment protocols. Furthermore, many members of this group are known to be more aggressive than Basal cell carcinoma and squamous cell carcinoma. There are no consensus especially for approaches targeting lymph nodes. Closely following is necessary for early detection of recurrences and metastases.

show abstract

“…The cancer-specific mortality rate of SeC is 6-22% [8][9][10], and disease progression, including locoregional recurrence and distant metastasis, is reported in 4-28% [1,11,12]. Systemic therapy, including conventional chemotherapy, immunotherapy, and targeted therapies, can be considered in locally aggressive or metastatic SeCs, although the outcome data are scarce [5,13]. The use of conventional chemotherapy composed of Adriamycin and cyclophosphamide or platinum-based chemotherapeutic agents with either paclitaxel or 5-fluorouracil and folinic acid has been reported by some researchers [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas

Park

Shin

et al. 2021

Cancers

View full text Add to dashboard Cite

The biological behavior of sebaceous carcinoma (SeC) is relatively indolent; however, local invasion or distant metastasis is sometimes reported. Nevertheless, a lack of understanding of the genetic background of SeC makes it difficult to apply effective systemic therapy. This study was designed to investigate major genetic alterations in SeCs in Korean patients. A total of 29 samples, including 20 ocular SeCs (SeC-Os) and 9 extraocular SeCs (SeC-EOs), were examined. Targeted next-generation sequencing tests including 171 cancer-related genes were performed. TP53 and PIK3CA genes were frequently mutated in both SeC-Os and SeC-EOs with slight predominance in SeC-Os, whereas the NOTCH1 gene was more commonly mutated in SeC-EOs. In clinical correlation, mutations in RUNX1 and ATM were associated with development of distant metastases, and alterations in MSH6 and BRCA1 were associated with inferior progression-free survival (all p < 0.05). In conclusion, our study revealed distinct genetic alterations between SeC-Os and SeC-EOs and some important prognostic molecular markers. Mutations in potentially actionable genes, including EGFR, ERBB2, and mismatch repair genes, were noted, suggesting consideration of a clinical trial in intractable cases.

show abstract

Sebaceous carcinoma: controversies and their evidence for clinical practice

Cited by 25 publications

References 56 publications

Extraocular sebaceous carcinoma as a rapidly growing back mass: a case report

Extraocular sebaceous carcinoma as a rapidly growing back mass: a case report

A 20-Year Retrospective Analysis of Skin Cancers: Comparison of the First and Second Decades

Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas

Contact Info

Product

Resources

About